Efficacy of Empagliflozin in the Treatment of Experimental Myocardial Infarction

Introduction. With the emergence of empagliflozin in the pharmaceutical market, there has been an increase in publications on the primary and secondary pharmacodynamics of the drug, and the list of potential indications for the use of this sodium-glucose co-transporter inhibitor is increasing. Hypot...

Full description

Bibliographic Details
Main Authors: D. Yu. Ivkin, M. V. Krasnova, S. V. Okovity, A. A. Karpov, A. N. Kulikov, E. I. Yeletskaya
Format: Article
Language:Russian
Published: LLC Center of Pharmaceutical Analytics (LLC «CPHA») 2023-12-01
Series:Разработка и регистрация лекарственных средств
Subjects:
Online Access:https://www.pharmjournal.ru/jour/article/view/1640